INT28325

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 14
Disease Relevance 12.41
Pain Relevance 3.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Tst) RNA binding (Tst) plasma membrane (Tst)
Anatomy Link Frequency
CPA 2
CBT 2
Tst (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Clonidine 4 99.84 Very High Very High Very High
Neuropathic pain 2 97.76 Very High Very High Very High
antagonist 7 96.96 Very High Very High Very High
Sciatica 3 96.28 Very High Very High Very High
Morphine 3 96.08 Very High Very High Very High
withdrawal 21 95.60 Very High Very High Very High
agonist 21 95.60 Very High Very High Very High
Pain 23 95.36 Very High Very High Very High
narcan 9 94.84 High High
antidepressant 14 89.20 High High
Disease Link Frequency Relevance Heat
Pulmonary Disease 11 99.88 Very High Very High Very High
Diabetes Mellitus 15 99.78 Very High Very High Very High
Arrhythmias 2 Under Development 3 99.20 Very High Very High Very High
Dyspnea 4 99.00 Very High Very High Very High
Heart Rate Under Development 14 98.88 Very High Very High Very High
Sleep Initiation And Maintenance Disorders 271 98.64 Very High Very High Very High
Overactive Bladder 4 98.28 Very High Very High Very High
Neuropathic Pain 5 97.76 Very High Very High Very High
Cough 2 97.76 Very High Very High Very High
Increased Venous Pressure Under Development 4 97.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The second depends on an OVX-induced loss of TST decreases during the dark phase as measured by telemetry.
Negative_regulation (loss) of TST
1) Confidence 0.51 Published 2007 Journal Endocrinology Section Abstract Doc Link 17122073 Disease Relevance 0.14 Pain Relevance 0.29
Clonidine caused decreases in TST and CBT, MDL-100907 caused increases in TST while decreasing CBT, and EE caused decreases in TST with minor CBT decreases only at the higher dose.
Negative_regulation (decreases) of TST in CBT associated with clonidine
2) Confidence 0.50 Published 2009 Journal J. Neurosci. Methods Section Abstract Doc Link 19135085 Disease Relevance 0.10 Pain Relevance 0.29
In the telemetry model, MDL-100907 attenuated the DOI-induced decrease in active-phase TST.
Negative_regulation (decrease) of TST
3) Confidence 0.38 Published 2004 Journal Brain Res. Section Abstract Doc Link 15527744 Disease Relevance 0.45 Pain Relevance 0.55
However, at the highest dose tested (10 mg/kg, i.p.), mirtazapine induced a small but significant decrease in TST followed by an increase in TST.
Negative_regulation (decrease) of TST
4) Confidence 0.38 Published 2006 Journal Brain Res. Section Abstract Doc Link 17067560 Disease Relevance 0.12 Pain Relevance 0.20
Distal loss of sweating detected on the TST was always associated with a subnormal quantitative sudomotor axon reflex response or abnormal electromyographic findings, an indication of a distal axonal neuropathy.
Negative_regulation (loss) of TST associated with neuropathic pain
5) Confidence 0.37 Published 1989 Journal Mayo Clin. Proc. Section Abstract Doc Link 2747292 Disease Relevance 1.34 Pain Relevance 0.34
Clonidine caused decreases in TST and CBT, MDL-100907 caused increases in TST while decreasing CBT, and EE caused decreases in TST with minor CBT decreases only at the higher dose.
Negative_regulation (decreases) of TST in CBT associated with clonidine
6) Confidence 0.37 Published 2009 Journal J. Neurosci. Methods Section Abstract Doc Link 19135085 Disease Relevance 0 Pain Relevance 0.28
SCLM for 7 days reduced immobility time in the TST and FST in mice and also decreased immobility time at 70 and 140 mg/kg (p.o.) in the FST in rats.
Negative_regulation (reduced) of TST
7) Confidence 0.16 Published 2006 Journal Life Sci. Section Abstract Doc Link 16546221 Disease Relevance 0 Pain Relevance 0.25
It produces a decrease in circulating Tst and androstenedione levels through a reduction in circulating LH and has been used as an effective treatment for hirsutism.[21] CPA is available in combination with ethinyl estradiol (EE) (2 mg CPA and 35 ?
Negative_regulation (reduction) of Tst in CPA associated with hirsutism
8) Confidence 0.05 Published 2010 Journal Indian Journal of Dermatology Section Body Doc Link PMC2856356 Disease Relevance 1.64 Pain Relevance 0.11
It produces a decrease in circulating Tst and androstenedione levels through a reduction in circulating LH and has been used as an effective treatment for hirsutism.[21] CPA is available in combination with ethinyl estradiol (EE) (2 mg CPA and 35 ?
Negative_regulation (decrease) of Tst in CPA associated with hirsutism
9) Confidence 0.05 Published 2010 Journal Indian Journal of Dermatology Section Body Doc Link PMC2856356 Disease Relevance 1.68 Pain Relevance 0.11
In a sample of adults with chronic insomnia, Zammit and colleagues (2004) found that all sleep parameters (SL, TST, WASO, and SE) improved under the 3 mg dose condition, while all parameters except for wake time after sleep onset improved in the 2 mg dose condition.
Negative_regulation (improved) of TST associated with sleep initiation and maintenance disorders
10) Confidence 0.03 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2685268 Disease Relevance 0.37 Pain Relevance 0.14
Results indicate that the eszopiclone 2 mg group had significantly improved SL (p = 0.0034), TST (p = 0.0003), WASO (p ?
Negative_regulation (improved) of TST
11) Confidence 0.03 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2685268 Disease Relevance 0.28 Pain Relevance 0
In a sample diagnosed with chronic primary insomnia, Krystal and colleagues (2005) found that a dose of 3 mg of eszopiclone significantly improved SL, TST, NWAK, WASO, and quality of sleep (p ?
Negative_regulation (improved) of TST associated with sleep initiation and maintenance disorders
12) Confidence 0.03 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2685268 Disease Relevance 0.47 Pain Relevance 0.12
Studies suggest that patients with diabetes mellitus (DM) have decreased TST and impaired sleep quality secondary14 to nocturia and neuropathic pain.15 There is accumulating evidence that poor sleep impairs glucose metabolic control.
Negative_regulation (decreased) of TST associated with diabetes mellitus, neuropathic pain and overactive bladder
13) Confidence 0.03 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778437 Disease Relevance 2.61 Pain Relevance 0.27
Patients with COPD have decreased total sleep times (TST), SWS, and REM sleep.10 Shortness of breath, nocturnal cough, and wheezing worsen sleep.12 This leads to fatigue and sleep deprivation, which undermine the work of breathing and impair gas exchange.
Negative_regulation (decreased) of TST associated with respiratory sounds, pulmonary disease, fatigue, cough, sleep disorders and dyspnea
14) Confidence 0.02 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778437 Disease Relevance 3.20 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox